Acorda Therapeutics Inc (ACORQ)
0.59
-0.02
(-2.48%)
USD |
OTCM |
May 20, 10:13
Acorda Therapeutics Cash from Operations (TTM): -27.15M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -27.15M |
| December 31, 2023 | -13.98M |
| September 30, 2023 | -1.90M |
| June 30, 2023 | -11.35M |
| March 31, 2023 | -14.30M |
| December 31, 2022 | -20.92M |
| September 30, 2022 | -26.75M |
| June 30, 2022 | -33.92M |
| March 31, 2022 | -28.10M |
| December 31, 2021 | -41.35M |
| September 30, 2021 | -43.14M |
| June 30, 2021 | -37.03M |
| March 31, 2021 | -49.12M |
| December 31, 2020 | -61.01M |
| September 30, 2020 | -73.88M |
| June 30, 2020 | -95.33M |
| March 31, 2020 | -89.45M |
| December 31, 2019 | -128.17M |
| September 30, 2019 | -129.08M |
| June 30, 2019 | -26.55M |
| March 31, 2019 | 44.60M |
| December 31, 2018 | 150.79M |
| September 30, 2018 | 223.66M |
| June 30, 2018 | 197.26M |
| March 31, 2018 | 151.26M |
| Date | Value |
|---|---|
| December 31, 2017 | 97.14M |
| September 30, 2017 | 63.38M |
| June 30, 2017 | 17.34M |
| March 31, 2017 | -2.466M |
| December 31, 2016 | 29.65M |
| September 30, 2016 | 25.20M |
| June 30, 2016 | 41.63M |
| March 31, 2016 | 54.43M |
| December 31, 2015 | 38.48M |
| September 30, 2015 | 29.37M |
| June 30, 2015 | 45.64M |
| March 31, 2015 | 61.09M |
| December 31, 2014 | 74.65M |
| September 30, 2014 | 80.62M |
| June 30, 2014 | 61.64M |
| March 31, 2014 | 51.24M |
| December 31, 2013 | 39.28M |
| September 30, 2013 | 36.84M |
| June 30, 2013 | 37.41M |
| March 31, 2013 | 41.45M |
| December 31, 2012 | 52.12M |
| September 30, 2012 | 68.35M |
| June 30, 2012 | 91.09M |
| March 31, 2012 | 81.47M |
| December 31, 2011 | 66.34M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-129.08M
Minimum
Sep 2019
-1.90M
Maximum
Sep 2023
-47.62M
Average
-35.48M
Median
Cash from Operations (TTM) Benchmarks
| BioSig Technologies Inc | -17.31M |
| Verve Therapeutics Inc | -143.54M |
| Spectral AI Inc | -- |
| AIM ImmunoTech Inc | -21.27M |
| Protalix BioTherapeutics Inc | 5.868M |